Trastuzumab (Herceptin) – Full Drug Profile and Clinical Guide

-

Trastuzumab (Herceptin)

⚠️ Black Box Warning – Serious Risks of Trastuzumab (Herceptin)

Trastuzumab (Herceptin) has been associated with anaphylactic reactions, infusion-related events, and acute respiratory distress syndrome, which can be fatal.
Other serious risks include:

  • Left ventricular ejection fraction (LVEF) reduction
  • Severe heart failure, thrombus formation, stroke, and cardiac death
  • Fetal risks such as pulmonary hypoplasia and skeletal malformations

⚠️ Do not confuse Trastuzumab (Herceptin) with ado-trastuzumab emtansine

Trastuzumab (Herceptin) Drug Classification

Pharmacotherapeutic Class:

  • HER2 receptor antagonist
  • Monoclonal antibody

Clinical Class:

  • Antineoplastic agent used in targeted cancer therapy

Approved Medical Uses of Trastuzumab (Herceptin)

Trastuzumab (Herceptin) is indicated for the treatment of:

  • HER2-overexpressing breast cancer (adjuvant setting)
  • Metastatic breast cancer
  • Metastatic gastric or gastroesophageal junction adenocarcinoma (in previously untreated patients)

Off-label Use:

Used with lapatinib in HER2-positive metastatic breast cancer patients:

  • Not previously treated with anti-HER2 therapy
  • Whose disease progressed on prior trastuzumab therapy

Trastuzumab (Herceptin) Precautions and Contraindications

Contraindications:

  • Known hypersensitivity to Trastuzumab (Herceptin)

Use with Caution in Patients with:

  • Cardiac disease or dysfunction
  • Pulmonary disease or high tumor burden in the lungs
  • Pregnancy

How Trastuzumab (Herceptin) Works – Mechanism of Action

Trastuzumab (Herceptin) binds to the extracellular domain of the HER2 receptor, blocking tumor cell proliferation in HER2-positive cancers.

Therapeutic Effects:

  • Inhibits tumor cell growth
  • Mediates antibody-dependent cellular cytotoxicity (ADCC)

Pharmacokinetics of Trastuzumab (Herceptin)

  • Half-life: 11–23 days
  • Long elimination phase supports weekly or tri-weekly dosing

Trastuzumab (Herceptin) and Special Population Considerations

Pregnancy/Lactation:

  • Use effective contraception during treatment and for 7 months after the last dose
  • Breastfeeding is not recommended

Pediatric Use:

  • Safety and efficacy of Trastuzumab (Herceptin) in children are not established

Elderly:

  • Increased risk of cardiac dysfunction; may require dose adjustment

Drug and Food Interactions with Trastuzumab (Herceptin)

Drug Interactions:

  • May increase toxicity of belimumab
  • May reduce effectiveness of paclitaxel (conventional)

Herbal and Food Interactions:

  • No significant herbal or food interactions reported

Trastuzumab (Herceptin) Availability and Formulations

  • Prescription only (Rx)
  • Available as Powder for Reconstitution:
    • 150 mg
    • 440 mg

IV Administration and Handling of Trastuzumab (Herceptin)

Reconstitution:

  • 440 mg vial → mix with 20 mL Bacteriostatic Water for Injection
  • 150 mg vial → mix with 7.4 mL Sterile Water for Injection
  • Final concentration: 21 mg/mL

Infusion Instructions:

  • Do NOT give IV push or bolus
  • Add to 250 mL 0.9% NaCl (never D5W)
  • Gently mix and administer:
    • Loading dose: 4 mg/kg over 90 minutes
    • Maintenance: 2 mg/kg over 30 minutes

Storage:

  • Refrigerate vials and solutions
  • Reconstituted vials (with preservative): stable for 28 days
  • Diluted infusion: stable for 24 hours (refrigerated)

IV Incompatibilities of Trastuzumab (Herceptin)

  • Do not mix with D5W or any other medications
  • Do not substitute with ado-trastuzumab emtansine

Trastuzumab (Herceptin) Dosage and Administration Guidelines

Adjuvant Breast Cancer Treatment (IV – Adults/Elderly):

With PACLitaxel or DOCEtaxel:

  • 4 mg/kg → then 2 mg/kg weekly × 12 weeks
  • Then 6 mg/kg every 3 weeks → up to 52 weeks total

With DOCEtaxel/CARBOplatin:

  • Similar schedule, 18 weeks of weekly treatment

Post-chemotherapy:

  • Start with 8 mg/kg, followed by 6 mg/kg every 3 weeks

Metastatic Breast Cancer (IV – Adults/Elderly):

  • Alone or with PACLitaxel:
    • Start: 4 mg/kg over 90 minutes
    • Then 2 mg/kg weekly until disease progression

Gastric Cancer (IV – Adults/Elderly):

  • With CISplatin + capecitabine/fluorouracil (6 cycles), then monotherapy:
    • Initial: 8 mg/kg → followed by 6 mg/kg every 3 weeks

Dosage Adjustments for Cardiotoxicity in Trastuzumab (Herceptin)

If LVEF drops:

  • ≥16% from baseline, or
  • Below normal limits with ≥10% decrease
    → Hold treatment for 4 weeks, reassess LVEF
    → Resume if recovered in 4–8 weeks

Dose Adjustment in Renal or Hepatic Impairment

  • No dosage adjustments needed

Trastuzumab (Herceptin) Side Effects

Frequent (>20%):

  • Pain, fatigue, fever, chills, nausea, vomiting, diarrhea, cough, dyspnea

Occasional (5–15%):

  • Tachycardia, heart failure, flu-like symptoms, edema, insomnia, bone/joint pain

Rare (<5%):

  • Allergic reactions, anemia, leukopenia, neuropathy, herpes simplex

Serious Adverse Effects of Trastuzumab (Herceptin)

  • Cardiomyopathy and ventricular dysfunction
  • Heart failure (rare but serious)
  • Pancytopenia may occur

Nursing Considerations for Trastuzumab (Herceptin)

Baseline Assessment:

  • Assess left ventricular function via ECG, echocardiogram, or MUGA
  • Obtain CBC before and during treatment

Monitoring and Interventions:

  • Watch for cardiac decline
  • Assist patients with fatigue
  • Treat nausea and vomiting
  • Monitor bowel movement consistency

Patient Education: Trastuzumab (Herceptin) Safety Advice

  • Avoid vaccinations without medical approval
  • Stay away from individuals who received oral polio vaccine
  • Avoid crowds and people with infections


Comments

Post a Comment

Popular posts from this blog

Tryptyr (acoltremon) – The New FDA-Approved Breakthrough for Chronic Dry Eye

-
Image
✅  What Is Tryptyr (acoltremon)? Tryptyr-acoltremon In May 2025, the U.S. Food and Drug Administration (FDA) approved Tryptyr , a new and innovative treatment for chronic dry eye disease . The active ingredient, acoltremon , works by stimulating the body’s natural tear production—making it the first drug of its kind to target the root cause of dry eyes instead of just relieving symptoms. Tryptyr belongs to a new class of therapies that activate estrogen receptors in the lacrimal glands to restore the eye's natural moisture. 🧠 Why Are People Searching for Tryptyr? Users searching for Tryptyr are typically: Suffering from persistent dry eye symptoms (burning, itching, irritation) Seeking long-term relief beyond artificial tears Interested in the latest FDA-approved treatments Looking for an alternative to Restasis or Xiidra 🔬 How Tryptyr Works: A New Approach to Dry Eye Treatment Unlike traditional eye drops, Tryptyr stimulates the lacrimal glands through...
Read more

vinorelbine - Navelbine uses _side effects

-
Image
   Vinorelbine vinorelbine(vine-oh-rel-been) Navelbine   Classification vinorelbine   Therapeutic : antineoplastics Pharmacologic : vinca alkaloids   Pregnancy Category D  Indications vinorelbine Inoperable non–small-cell cancer of the lung in ambulatory patients (alone or with cisplatin).  Action of vinorelbine Binds to a protein (tubulin) of cellular microtubules, where it interferes with microtubule assembly. Cell replication is stopped as a result (cell cycle–specific for M phase).  Therapeutic Effects of vinorelbine  Death of rapidly replicating cells, particularly malignant ones.  Pharmacokinetics vinorelbine   Absorption : IV administration results in complete bioavailability.   Distribution : Highly bound to platelets and lymphocytes.  Metabolism and Excretion : Mostlymetabolized by the liver. At least one metabolite is active. Large amounts eliminated in feces; 11% excreted unchanged by the kidneys.  ...
Read more

Keytruda (Pembrolizumab): Effective Cancer Immunotherapy Option

-
Image
  Keytruda (Pembrolizumab) Cancer treatment has witnessed a significant shift with the advent of immunotherapy , and Keytruda (Pembrolizumab) stands at the forefront of this revolution. Recent studies have shown that immunotherapy can improve survival rates in various types of cancer. Keytruda , a leading immunotherapy drug, has been instrumental in this progress, offering new hope to patients with advanced cancer. By harnessing the power of the immune system, Pembrolizumab has demonstrated its efficacy in treating a range of cancers. Key Takeaways Cancer immunotherapy has emerged as a vital treatment option. Keytruda (Pembrolizumab) is a leading drug in cancer immunotherapy . Immunotherapy treatment can significantly improve cancer survival rates. Pembrolizumab has shown efficacy across various cancer types . The role of immunotherapy in cancer treatment continues to expand. Understanding Keytruda - Pembrolizumab In the realm of cancer treatment , Pembrolizumab , or Keyt...
Read more